Phil Lambert, PhD, Chief Scientific Officer at Satellos Bioscience, gave clinical insight on a new novel treatment and its mechanism of action in treating Duchenne muscular dystrophy in this video interview with NeurologyLive.
Dr. Lambert also discussed new phase 1 first-in-human data on SAT-3247 presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held March 16-19, in Dallas, Texas.
Watch the interview and read more here.
